Corcept Therapeutics CORT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's stock-based comp?
- Corcept Therapeutics (CORT) reported stock-based comp of $23.04M in Q1 2026.
- How has Corcept Therapeutics's stock-based comp changed year-over-year?
- Corcept Therapeutics's stock-based comp increased by 5.6% year-over-year, from $21.83M to $23.04M.
- What is the long-term trend for Corcept Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Corcept Therapeutics's stock-based comp has grown at a 18.4% compound annual growth rate (CAGR), from $42.93M to $84.5M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- High levels may signal dilution for shareholders, while consistent levels suggest standard talent retention practices.
- How does stock-based comp compare across companies?
- Common in high-growth pharmaceutical and tech sectors as a primary tool for talent acquisition.